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doi:10.1016/j.kjms.2012.04.022Abstract Hypertension can induce left ventricular hypertrophy (LVH), and the nitric oxide
(NO) pathway plays an important role in the pathogenesis of cardiac hypertrophy. This study
aimed to examine whether KMUP-1, a novel xanthine-based derivative, could inhibit LVH in
spontaneously hypertensive rats (SHRs) and to investigate potential mechanisms underlying
its antihypertrophic effects. Two groups of animals with chronic or subacute LVH were treated.
In the chronic LVH group, KMUP-1 (10 or 30 mg/kg/d orally) was administered for 28 days to both
normotensive rats and SHRs. In the subacute LVH group, KMUP-1 (0.5 mg/kg/d intraperitoneally)
or sildenafil (0.7 mg/kg/d intraperitoneally) was administered for 10 days with or without co-
treatment with the nitric oxide synthase (NOS) inhibitor N-omega-nitro-L-arginine (L-NNA;
20 mg/L orally). After treatment, the effects of KMUP-1 or sildenafil on hypertension, cardiac
hypertrophy, survival, expression of the NO/soluble guanylate cyclase (sGC)/protein kinase G
(NO/sGC/PKG) pathway in the aorta andleft ventricle, and calcineurin A/extracellular signal-
regulated kinase 1/2 (ERK1/2) signaling in the left ventricle were examined. In the chronic
LVH group, the SHRs developed hypertension with LVH over the 28 days. KMUP-1 attenuated
the hypertension and LVH, increased survival rate, enhanced endothelial NOS/cyclic guanosine
monophosphate/PKG (eNOS/cGMP/PKG) and decreased inducible NOS (iNOS) expression in thet of Pharmacology, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan First Road,
w (I.-J. Chen).
vier Taiwan LLC. All rights reserved.
568 J.-L. Yeh et al.Figure 1. Chemical structures of
KMUP-1$HCl.aorta and left ventricle of the SHRs. In the subacute LVH group, both KMUP-1 and sildenafil
administered for 10 days attenuated the LVH in SHRs, with enhanced eNOS/cGMP/PKG and sup-
pressed iNOS/calcineurin A/ERK1/2 expression in the left ventricle. In addition, both KMUP-1
and sildenafil attenuated L-NNA-induced LVH. KMUP-1 inhibition of hypertension-induced LVH
with associated upregulation of eNOS, downregulation of iNOS in both the aorta and left
ventricle, and attenuation of calcineurin A and ERK1/2 signaling in the left ventricle.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Left ventricular hypertrophy (LVH), which is characterized
by increased ventricular mass, develops in response to
numerous forms of cardiac stress, such as pressure or
volume overload [1]. Prolonged hypertension causes
vascular endothelial dysfunction and LVH, with associated
downregulation of endothelial nitric oxide synthase (eNOS)
in the endothelium [2e5]. eNOS and inducible NOS (iNOS)
are both important for the production of nitric oxide (NO)
and cyclic guanosine monophosphate (cGMP), while phos-
phodiesterase (PDE)-5A is the major enzyme for cGMP
hydrolysis. Enhanced cGMP production prevents the
hypertrophic signaling and antagonizes cyclic adenosine
monophosphate, resulting in an increase of protein kinase G
(PKG) in the heart [6]. Indeed, sildenafil, a PDE-5 inhibitor,
has been shown to have antihypertrophic activities by
blocking the degradation of cGMP [7,8].
Emerging evidence suggests that eNOS is involved in
ischemic protection and preservation of vascular contrac-
tility [9]. In fact, eNOS can regulate impaired endothelial NO
bioactivity in LVH, and the NOS inhibitor N-omega-nitro-L-
arginine (L-NNA) can reduce vascular relaxation via the NO/
cGMP pathway, thus worsening LVH. In addition, it has been
recently demonstrated that extracellular signal-regulated
kinase 1/2 (ERK1/2) and calcineurin A are both important
mediators signaling pathogenesis of cardiac hypertrophy
[10,11]. Therefore, a therapeutic strategy involving not only
the NO pathway, but also ERK 1/2 or calcineurin signaling,
may be beneficial in the treatment of hypertensive LVH.
KMUP-1 (Fig. 1), a xanthine-based eNOS/cGMP-enhancer,
has been reported to increase eNOS expression, inhibit iNOS
expression, and inhibit pulmonary hypertension [12e14].Wesildenafil$critric acid andhave previously shown that KMUP-1 can attenuate
isoprenaline-induced cardiac hypertrophy and inhibit right
ventricular hypertrophy induced by pulmonary artery
hypertension [14,15]. However, its effects on LVH induced by
hypertension and/or L-NNA have not been examined. In
addition, whether these effects are associated with modu-
lation of NOS in both the left ventricle and the aorta is
unknown. Thus, the current study addressed these questions
in rats with subacute or chronic hypertensive LVH. The
effects of KMUP-1 and sildenafil were also compared.
Materials and methods
Materials
KMUP-1, used in the salt form KMUP-1$HCl, was synthesized
in our laboratory. Sildenafil citrate was kindly supplied by
Cadila Healthcare Ltd. (Maninagar, India). L-NNA, a nonse-
lective NOS inhibitor, was purchased from Sigma-Aldrich
(St. Louis, MO, USA). Anti-eNOS antibody was obtained from
BD Biotechnology (New York, NY, USA), anti-PKG antibody
from Santa Cruz Biotechnology(Santa Cruz, CA, USA), anti-
iNOS, soluble guanylate cyclase (sGC)a1, calcineurin A, and
b-actin antibodies from Sigma, and anti-phospho ERK1/2
antibody from Cell Signaling Technology Inc. (Danvers, MA,
USA). KMUP-1$HCl was dissolved in distilled water and sil-
denafil was dissolved in vehicle (distilled water containing
0.5% methyl cellulose) for the experiments.
Experimental animals
Eight-week-old male spontaneously hypertensive rats
(SHRs) and Wistar-Kyoto (WKY) rats weighing 200e250 g
were purchased from the National Laboratory Animal
Breeding and Research Center (Taipei, Taiwan). The rats
were housed under constant temperature and controlled
illumination (light on between 7:30 AM and 19:30 PM) for 1
week before the experiment, i.e. beginning at week 9.
Food and water were available ad libitum. All protocols
were approved by the Animal Care and Use Committee of
Kaohsiung Medical University. The animal experiments were
divided into two groups: the chronic LVH group (28 days)
and the subacute LVH group (10 days).
Chronic LVH group (28 days)
In the chronic LVH group, WKY and SHR rats were studied in
a protocol of 28 days. WKY rats were divided into WKY-
control (WKY-CTL) and WKY-KMUP-1 groups. The WKY-CTL
rats received vehicle, while the WKY-KMUP-1 group
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into SHR-control (SHR-CTL) and SHR-KMUP-1 groups. The
SHR-CTL group received vehicle, and the SHR-KMUP-1 group
received KMUP-1 (10 or 30 mg/kg/d, given by gavage).
Subacute LVH group (10 days)
In the subacute LVH group, SHRs were randomly assigned to
six groups and studied in a protocol lasting 10 days. The
SHR-CTL group received intraperitoneal saline vehicle
injection daily for 10 days. The SHR-KMUP-1 group received
intraperitoneal KMUP-1$HCl (molecular weight 438.5 amu)
in a vehicle-containing dose of 0.5 mg/kg/d, and the SHR-
sildenafil group received intraperitoneal sildenafil citrate
(molecular weight 666.7) in a vehicle-containing dose of
0.7 mg/kg/d; i.e. both drugs were administrated at almost
equal molecular weights. The SHR-L-NNA group received L-
NNA in drinking water (20 mg/L). The SHR-L-NNA þ KMUP-1
group received both L-NNA (20 mg/L) and KMUP-1 (0.5 mg/
kg/d). The SHR-L-NNA þ sildenafil group received both L-
NNA in drinking water and sildenafil (0.7 mg/kg/d). SHRs in
all groups were fed with normal rat chow.
Systolic artery pressure
The systolic artery pressure (SAP) and heart rate were
recorded without anesthesia using the indirect tail cuff
method with a rat tail manometer-tachometer (MK-2000
Storage Pressure Meter; Muromachi Kikai Co., Ltd, Tokyo,
Japan). The rats in the chronic group were restrained in
a Plexiglass holder at a temperature of 37 C for 15e20
minutes to raise their body temperature. The increased
temperature leads to dilatation of the caudal artery, which
allowed us to detect pressure pulse easily. In all rats, at
least three consecutive measurements were obtained, and
the average was reported as the SAP. Changes in SAP were
calculated by subtracting the SAP at the beginning from the
SAP measured each week. Comparisons were made from
the beginning to the end of treatment. Changes of SAP in
the subacute group are not shown.
Survival and heart weight indices
The number of survivors in each group was recorded daily
until the end of the study. After the defined treatment
period, the rats were sacrificed by intraperitoneal injection
of 40 mg/kg pentobarbital sodium. The heart was perfused
with saline, and the heart weight and body weight were
recorded. The heart weight index was calculated by
dividing the heart weight by the body weight [9].
Plasma nitrite/nitrate
As previously described, plasma nitrite/nitrate (NOx) was
measured by the Griess reaction [15]. In brief, blood was
sampled from the aorta and centrifuged at 370 g for 20
minutes at 4 C. The supernatants were incubated with the
Griess reagent at room temperature. Ten minutes later, the
absorbance was measured at 540 nm using an automatic
plate reader, and the NOx concentrations were expressed as
micromoles and calculated using a standard curve for NOx.Myocardial cGMP
Frozen myocardial tissue samples in liquid nitrogen were
ground to a fine powder in a stainless steel mortar. Once
the liquid nitrogen had evaporated, the frozen tissue was
weighed and homogenized in 10 volumes of 0.1 M HCl to
stop the action of PDEs. Centrifugation was at 600 g at room
temperature, and the supernatant was collected for
quantitative immunoassay of cGMP according to the
manufacturer’s instructions (Enzo Life Sciences Interna-
tional, Inc. Plymouth Meeting, PA, USA).
Western blot analysis
eNOS, iNOS, sGCa, PKG, calcineurin A, phospho-ERK1/2, and
total ERK1/2 proteins were measured by western blotting as
described previously [12e14]. Briefly, the aorta and left
ventricle, isolated from surviving rats, were homogenized
separately in ice-cold lysis buffer. After sonication, the
homogenate was centrifuged at 13,000 gfor 60 minutes at
4 C, and the supernatant was recovered as the total cellular
protein. Total protein from each sample was separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis
on 10% acrylamide gels, transferred to a polyvinylidine
difluoride-plus membrane, and then blocked with 5% nonfat
dry milk in Tris-buffered saline. Membranes were subse-
quently incubatedwith a 1:1000 dilution of eNOS, iNOS, PKG,
calcineurin A, and ERK1/2 antibodies. Proteins were detec-
ted with horseradish peroxidase-conjugated secondary
antibody (1:1000 dilution; Chemicon, Temecula, CA, USA).
The immunoreactive bands were detected by chem-
iluminescence reagents developed by Hyperfilm (Kodak,
Rochester, NY, USA), and the loading control protein beta-
actin was used in the analyses.
Statistical analysis
The results are expressed as mean  standard error.
Statistical differences were determined by Student t test in
unpaired samples. Whenever a control group was compared
with KMUP-1 and other treated groups, one-way analysis of
variance (ANOVA) or two-way repeated-measures ANOVA
was used. When ANOVA manifested a statistical difference,
Dunnett’s test was applied. A value of p < 0.05 was
considered significant.
Results
Effects on SAP and cardiac hypertrophy in the
chronic LVH group
In the chronic LVH group, the control basal levels of SAP in
WKY rats and SHRs were 124.4  6.2 and 151  3.9 mmHg,
respectively. After 28 days, this increased to 134.6  3.2
and 181.6  5.7 mmHg, respectively. WKY rats treated with
KMUP-1 (10 mg/kg/d orally) for 28 days did not show
a significant reduction in the change in SAP (Fig. 2A). In
SHRs, KMUP-1 (10 and 30 mg/kg/d orally) prevented the
development of hypertension (Fig. 2A). As shown in Fig. 2B,
SHRs developed cardiac hypertrophy, indicated by an
Figure 2. Effects of KMUP-1 on tail systolic artery pressure (SAP) changes in spontaneously hypertensive rats (SHRs) and Wistar-
Kyoto (WKY) rats. KMUP-1 (10 or 30 mg/kg orally) caused a reduction in SAP in SHRs but not WKY rats. SAP changes were more
inhibited by KMUP-1 in SHRs than in WKY rats, compared with vehicle control (A). Each bar represents the mean  standard error
(n Z 15 rats/group). * p < 0.05, ** p < 0.01 versus the SHR-CTL group. KMUP-1 also significantly reduced the heart weight/body
weight (HW/BW) ratio of SHR-CTL rates (B).* p < 0.05 versus the WKY-CTL group; þ p < 0.05 versus the SHR-CTL group.
CTL Z control.
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KMUP-1 (10 and 30 mg/kg/d) significantly attenuated the
hypertrophic responses in SHRs.Effects on survival and cardiac hypertrophy in the
subacute LVH group
KaplaneMeier survival plots of SHRs in the subacute LVH
group are shown in Fig. 3A. At the termination of the study,
the survival rates of the control SHRs and the KMUP-1-
treated and sildenafil-treated groups were all 100%. TheFigure 3. Effects of KMUP-1 and sildenafil alone or in combinat
taneously hypertensive rats (SHRs) over 10 days. KMUP-1 and sildena
survival (A) but did reduce the heart weight/body weight (HW/BW) r
SHR-L-NNA group than the SHR-CTL group. The antihypertrophic ef
L). Each bar represents the mean  standard error (n Z 15 rats
** p < 0.01 versus the SHR-KMUP-1 group; z p < 0.01 versus the SHsurvival rate of the SHR-L-NNA group was 80% (12/15). The
SHR-L-NNA þ KMUP-1 group and the SHR-L-NNA þ sildenafil
group both had an 87% survival rate (13/15), indicating that
KMUP-1 and sildenafil tended to improve the survival of
SHRs, although this did not reach a significant difference.
As shown in Fig. 3B, intraperitoneal injection of KMUP-1
(0.5 mg/kg/d) and sildenafil (0.7 mg/kg/d) for 10 days
attenuated cardiac hypertrophy in SHRs. The L-NNA
(20 mg/L) group had more profound cardiac hypertrophy
compared with the SHR-CTL group. In the presence of L-
NNA, neither KMUP-1 nor sildenafil caused a significant
reduction in cardiac hypertrophy.ion with N-omega-nitro-L-arginine (L-NNA) on survival of spon-
fil alone or in combination with L-NNA did not significantly alter
atio in SHRs (B).The HW/BW ratio was significantly higher in the
fects of KMUP-1 and sildenafil were inhibited by L-NNA (20 mg/
/group). # p < 0.05, ## p < 0.01 versus the SHR-CTL group;
R-sildenafil group. CTL, control.
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In the chronic LVH group, KMUP-1 (10 mg/kg/d orally)
significantly increased the expression of eNOS, sGC, and
PKG in the aorta of WKY rats (Fig. 4A, C, D). KMUP-1 (30 mg/
kg/d orally) also increased the expression of eNOS, sGC,
and PKG in SHRs. Expression of iNOS was profoundly
increased in SHRs compared with the WKY-CTL group
(Fig. 4B). Treatment with KMUP-1 (30 mg/kg/d orally)
significantly attenuated the expression of iNOS in SHRs
compared with the SHR-CTL group (Fig. 4B).
Effects on left ventricular eNOS and iNOS
In the chronic LVH group, oral administration of KMUP-1
(10 mg/kg/d) significantly increased ventricular eNOS
expression in SHRs and WKY rats. The eNOS expression in
the SHR-CTL and SHR-KMUP-1 groups was less than that inFigure 4. Effects of KMUP-1 on endothelial nitric oxide synthase
(sGC) (C), and protein kinase G (PKG) (D) expression in the aorta of
rats. KMUP-1 (10 mg/kg) significantly increased the expression of eN
also significantly increased eNOS, sGC, and PKG expression, com
increased in the SHR-CTL group, compared with the WKY-CTL grou
from six experiments with SHRs and WKY rats were analyzed. Each
the WKY-CTL group; * p < 0.05, ** p < 0.01 versus the SHR-CTL grothe WKY-CTL group (Fig. 5A). In the subacute LVH group,
both KMUP-1 (0.5 mg/kg/d intraperitoneally) and sildenafil
(0.7 mg/kg/d intraperitoneally) increased expression of
eNOS in SHRs (Fig. 5B).
In the chronic LVH group, the increased expression of
iNOS in SHRs was significantly decreased by treatment
with KMUP-1 (10 mg/kg/d) (Fig. 5C). KMUP-1 (10 mg/kg/d)
had no effect on iNOS in the WKY group. In the subacute
LVH group, treatment with KMUP-1 (0.5 mg/kg/d intraperi-
toneally) or sildenafil (0.7 mg/kg/d intraperitoneally)
significantly decreased the expression of iNOS in SHRs
(Fig. 5D).
Effects on plasma NOx
In the chronic LVH group, we sampled the plasma of rats
that received oral KMUP-1 (10 mg/kg/d) to measure NOx. As
seen in Fig. 6A, there were no differences in plasma NOx(eNOS) (A), inducible NOS (iNOS) (B), soluble guanylate cyclase
spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY)
OS, sGC, and PKG in the aorta of WKY rats. KMUP-1 (30 mg/kg)
pared with the SHR-CTL group. iNOS expression was sharply
p, and was significantly reduced by KMUP-1 (30 mg/kg). Data
value represents the mean  standard error. ## p < 0.01 versus
up. CTL, control.
Figure 5. Effects of KMUP-1 and sildenafil on endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) protein
expression in the left ventricle of spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. KMUP-1 significantly
increased eNOS and decreased iNOS expression. Data from densitometry analyses are presented as the relative ratio of eNOS (A, B)
or iNOS (C, D) protein/beta-actin protein. Each value represents the mean  standard error (nZ 6). * p < 0.05, ** p < 0.01 versus
the WKY-CTL group; ## p < 0.01 versus the SHR-CTL group. CTL Z control.
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whereas SHRs treated with KMUP-1 were found to have
higher plasma NOx levels than the SHR-CTL group and the
WKY-CTL group.
In the subacute LVH group, treatment with KMUP-1 and
sildenafil significantly increased the plasma NOx in SHRs
(Fig. 6B), whereas treatment with L-NNA significantly
reduced the basal production of NOx (Fig. 6B). Treatment
with KMUP-1 and sildenafil prevented this L-NNA-induced
reduction (Fig. 6B).
Effects on left ventricular cGMP and PKG
In the chronic LVH group, ventricular cGMP and PKG levels
in SHRs were lower than those in WKYs (Figs. 6C and 7A).
KMUP-1 (10 mg/kg/d) significantly increased cGMP and PKG
expression in the left ventricle of normotensive and
hypertensive rats.Similarly, in the subacute LVH group, as shown in
Figs. 6D and 7B, both KMUP-1 (0.5 mg/kg/d intraperitone-
ally) and sildenafil (0.7 mg/kg/d intraperitoneally) signifi-
cantly increased cGMP and PKG expression and abolished L-
NNA-induced downregulation of cGMP and PKG. L-NNA
alone significantly decreased cGMP and PKG expression in
SHRs.
Effects on left ventricular calcineurin A and ERK1/2
In the chronic LVH group, (Fig. 8A, C), the SHR-CTLgroup
had higher expression levels of calcineurin A and phos-
phorylated ERK1/2 than WKY-CTL rats (p < 0.01). Treat-
ment with KMUP-1 (10 mg/kg/d orally) significantly
attenuated the expression of calcineurin A and phosphor-
ylated ERK1/2 in SHRs.
In the subacute LVH group, as seen in Fig. 8B and 8D,
both KMUP-1 and sildenafil significantly inhibited the
Figure 6. Effects of KMUP-1 and sildenafil on nitric oxide concentration (NOx) in plasma, and cyclic guanosine monophosphate
(cGMP) level in the left ventricle of spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. KMUP-1 and sildenafil
significantly increased the production of NOx (A, B) and cGMP (C, D). NOx production by oral KMUP-1 (10 mg/kg/d for 28 days) and
the combination of N-omega-nitro-L-arginine (L-NNA) and KMUP-1 (0.5 mg/kg/d for 10 days intraperitoneally) or sildenafil (0.7 mg/
kg/d for 10 days intraperitoneally) were measured by the level of NO metabolites, nitrite (NO2
e) and nitrate (NO3
e), in plasma. Each
value represents the mean  standard error (n Z 6). (A), p < 0.05 versus the SHR-CTL group; (B) # p < 0.05 versus the SHR-CTL
group; ** p < 0.01 versus the SHR-L-NNA group; (C) * p < 0.05, ** p < 0.01 versus the WKY-CTL group; p < 0.05 versus the SHR-CTL
group; (D) # p < 0.05 versus the SHR-CTL group; * p < 0.05, ** p < 0.01 versus the SHR-L-NNA group. CTL Z control; L-NNA Z N-
omega-nitro-L-arginine.
KMUP-1 prevents ventricular hypertrophy 573expression of calcineurin A and phosphorylated ERK1/2.
SHRs treated with L-NNA were found to have an increase in
calcineurin A and phosphorylated ERK1/2 expression
(Fig. 8B, D), which could be attenuated by KMUP-1 (0.5 mg/
kg/d) and sildenafil (0.7 mg/kg/d). KMUP-1 was more
potent than sildenafil in inhibiting calcineurin A and ERK1/2
expression.
Discussion
We have recently shown that KMUP-1 attenuated
isoprenaline-induced cardiac hypertrophy through the NO/
cGMP pathway and signaling transduction in myocardium
and cardiomyocytes [15]. This study further suggests that
KMUP-1 can alleviate LVH induced by hypertension or L-
NNA. In addition, we found that KMUP-1 restored eNOS in
the aorta but downregulated iNOS in the left ventricle, both
of which could mediate therapeutic effects on hypertensive
LVH. Furthermore, we found that KMUP-1 had more marked
suppressive effects on calcineurin A and ERK1/2 than sil-
denafil in hypertensive LVH.In this study, increased eNOS and decreased iNOS
expression are involved in the antihypertrophic effects of
KMUP-1 in SHRs. This finding is consistent with the growing
evidence that NO may have beneficial or deleterious
effects on myocardium if derived from eNOS or iNOS,
respectively [16,17]. NO stimulates cGMP synthesis through
sGC activation, and the downstream cGMP-dependent PKG
modulates cardiac remodeling and dysfunction [18]. NO
formation and cGMP enhancement can improve the
contractile function and sarcolemmal integrity of the heart
[19]. Therefore, we assume that the cardioprotective
effects conveyed by KMUP-1 in SHRs might be attributed to
both increased eNOS and decreased iNOS expression.
precisely How KMUP-1 upregulates eNOS and inhibits iNOS
in the hypertensive LVH is, however, not clear and warrants
further studies.
We speculate that the mechanisms underlying the
discrepant regulation of eNOS and iNOS by KMUP-1 are
associated with its antioxidative and anti-inflammatory
effects. It is well known that reactive oxygen species can
decrease eNOS activity [20]. In addition, there is some
Figure 7. Effect of KMUP-1 and sildenafil on protein kinase G (PKG) protein expression in the left ventricles of spontaneously
hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. KMUP-1 and sildenafil significantly increased PKG expression. Each value
represents the mean  standard error (nZ 6). (A) * p < 0.05, ** p < 0.01 versus the WKY-CTL group; p < 0.05 versus the SHR-CTL
group; (B) ## p < 0.01 versus the SHR-CTL group; ** p < 0.01 versus the SHR-L-NNA group. CTLZ control; L-NNAZ N-omega-nitro-L-
arginine.
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[21]. In fact, we have found that KMUP-1 increased eNOS
activity and also had antioxidative activity. Accordingly, we
speculate that, with its ability to enhance cGMP produc-
tion, KMUP-1 might increase eNOS activity due to its anti-
oxidant effect.
Regarding the suppressive effect of KMUP-1 on iNOS,
our previous study showed that KMUP-1 was able to
suppress the iNOS expression induced by tumor necrosis
factor alpha (TNF-a) [13].It is known that in a hypertensive
status, there is increased production of cytokines such as
TNF-a [22]. Therefore, it is possible that, in SHRs, the
mechanisms by which KMUP-1 suppresses iNOS expression
may be direct inhibition of the effects of TNF-a or indirect
suppression of TNF-a production as a result of resolved
hypertension.
Interestingly, even though in the present study the
expression of eNOS was lower and the expression of iNOS
higher in SHRs than WKY rates, there was no difference in
the plasma levels of NOx between SHR and WKY rats. It is
well known that iNOS-derived NO formation is markedly
greater than that from eNOS. Nevertheless, it should be
also noted that plasma NOx is an indirect indicator of the
total endogenous production of NO from nonspecific tissue
[23]. Therefore, it is possible that iNOS and eNOS, from
either aorta or left ventricle, may both contribute to the
production of plasma NOx. Accordingly, we assume that, in
SHRs, NO production induced by upregulated iNOS may be
offset by that induced by downregulated eNOS, with the
net result of a slight tendency toward a higher but not
significantly different NO production when compared with
the levels in WKY rats.
A novel finding of the present study is that the anti-
hypertrophic effects exerted by KMUP-1 are associated with
regulation of eNOS and iNOS not only in the left ventricle,but also in the aorta. We speculate that KMUP-1 could
affect vascular eNOS expression and that it first exerted
antihypertensive effects [14]. Following this effect, KMUP-1
then improved LVH and subsequently reduced ventricular
iNOS expression. In our study, the antihypertensive effect
of KMUP-1 was markedly significant, so it could be caused
by the vasodilatory action of KMUP-1 on enhancing endo-
thelial NOS expression. Inhibition of PDE-5 by KMUP-1 can
block the degradation of cGMP, thereby increasing its
intracellular levels and evoking potent vasodilatory
responses [12, 14]. The dual effects on both aorta and
myocardium may play a predominant role of KMUP-1 in
reducing hypertensive LVH. However, it should also be
noted that KMUP-1 could lower the blood pressure in
normotensive WKY rats even at low dosage, suggesting that
hypotension might be a side effect of concern in future
studies using higher doses.
ERK1/2 is activated in response to hypertrophic agonists
and is itself a contributor to hypertrophy [24]. Calcineurin A
has been reported to regulate the nuclear factor of acti-
vated T cells-dependent iNOS expression and car-
diomyocyte protection [25]. In addition, calcineurin A can
activate ERK1/2, and thus mediate cell proliferation and
differentiation [26]. In our study, calcineurin A and ERK1/2
phosphorylation were increased in SHRs receiving L-NNA,
and these effects were attenuated by both KMUP-1 and
sildenafil, suggesting that they may also exert their car-
dioprotective properties through ERK1/2 and calcineurin A
signaling pathways.
In summary, the present study indicates that KMUP-1 can
improve hypertension-induced LVH and associated down-
regulation of eNOS in aorta and upregulation of iNOS in left
ventricle [8,27]. In addition, its antihypertrophic effects
are possibly mediated by signaling of calcineurin A and
ERK1/2 pathways in the myocardium.
Figure 8. Effects of KMUP-1 and sildenafil on calcineurin A and extracellular signal-regulated kinase 1/2 (ERK1/2) protein
expression in the left ventricles of spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. KMUP-1 and sildenafil
inhibited hypertension-induced calcineurin A (A, B) and ERK1/2 (C, D) protein expression. Each value represents the
mean  standard error (n Z 6). (A) ** p < 0.01 versus the WKY-CTL group; ## p < 0.01 versus the SHR-CTL group; (B) # p < 0.05;
## p < 0.01 versus the SHR-CTL group; ** p < 0.01 versus the SHR-L-NNA group; (C) ** p < 0.01 versus the WKY-CTL group;
## p < 0.01 versus the SHR-CTL group; (D) # p < 0.05; ## p < 0.01 versus the SHR-CTL group; ** p < 0.01 versus the SHR-L-NNA
group. CTL Z control; L-NNA Z N-omega-nitro-L-arginine.
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